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INTRODUCTION
Interferons are cytokines with antiviral, anti-proliferative
and immuno-modulation property with ability to interfere
with viral replication within host cells. They activate
immune cells such as Natural Killer (NK) and cytotoxic-T
cells and increase the ability of uninfected host cells to
resist new infections by virus, by producing certain
proteins known as interferon stimulated genes.1
Interferon-alpha (IFN-alpha) therapy with or without
other antiviral agents is standard care of treatment in
patients with hepatitis-C.
We report a case of a patient with hepatitis-C, treated
with IFN-alpha who developed ocular complication.
CASE REPORT
A 30-year male presented with gradual, painless
decrease in vision in his both eyes for the last few
weeks. He had hepatitis-C diagnosed 12 months ago
and was treated with IFN-alpha (pegylated) therapy for 6
months. The patient had no history of Diabetes Mellitus
(DM), Hypertension (HTN) or any other systemic
disorder. He was not on any medical therapy at present.
His Fasting Sugar (FBS), glycated haemoglobin (HbA1c),
Complete Blood Count (CBC), lipids and autoimmune
profile were all within normal limits. Ocular examination
revealed his Best Corrected Visual Acuity (BCVA) of
6/18 in his right eye and 6/12 in his left eye. The bio-
microscopic examination showed anterior segments
unremarkable in his both eyes with Intraocular Pressure
(IOP) of 10 mmHg in his either eye. Fundus examination
with +90D volk lens revealed about two disc diameter,
subfoveal lesions in both eyes (Figure 1). Fundus Fluores-
cein Angiography (FFA) showed hyper-fluorescein
areas over macula, due to filling of choroidal neovas-
cular membranes (Figure 2). The Optical Coherence
Tomography (OCT) confirmed the presence of subfoveal
choroidal neovascular membranes (Figure 3 and 4).
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ABSTRACT
A 30-year-old male presented with gradual decrease in vision in his both eyes after the use of interferon alpha for his
hepatitis-C. Ocular examination of patient included, Best Corrected Visual Acuity (BCVA), fundus photographs, Fundus
Fluorescein Angiography (FFA) and Optical Coherence Tomography (OCT). His BCVA was recorded as 6/18 in the right
eye and 6/12 in the left eye. The anterior segments were unremarkable, with normal intraocular Pressure (IOP) in his both
eyes. Both fundi revealed the presence of bilateral Choroidal Neovascularization (CNV), confirmed on FFA and OCT. To
the best of authors' knowledge, simultaneous presence of CNV in both eyes is not reported in the literature.
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Figure 1: Coloured photographs of fundus.
Figure 2: FFA of both eyes.
Figure 3: OCT of right and left eyes.
 
The patient was advised and given injection Bevacizumab
(Avastin) 1.25 mg intravitreally in his both eyes under
sterile condition in operating room.
DISCUSSION
To the best of authors' knowledge, simultaneous
presence of CNV in both eyes after IFN-alpha therapy is
not reported in the literature previously. Retinal ischemia
has been a common manifestation of IFN treatment in
patients with hepatitis-C, characterized by presence of
microaneurysms, retinal haemorrhages and cotton-wool
spots.2 The prevalence of retinopathy is variable among
different studies. Panetta suggested an overall low
occurrence of retinopathy at 3.8% in 180 patients treated
with IFN-alpha,3 Kadayifcilar and co-workers evaluated
36 patients with chronic active hepatitis receiving IFN-
alpha for one year and found 15 patients (42%) having
retinopathy with cotton-wool formation and splinter
haemorrhages.4
The underlying patho-physiology for IFN induced
retinopathy is not known. The presence of retinal
haemorrhages and cotton-wool areas suggest an
ischemic response. The possible mechanism for
retinopathy is believed to be due to immune system
dysfunction, deposition of immune complexes in the
retinal vessels and increase adhesions of activated
leucocytes.5 Similar mechanism can be argued for
choroidal ischemia resulting in Choroidal Neovas-
cularization (CNV). The elevated level of Vascular
Endothelial Growth Factor (VEGF) after IFN-alpha
therapy has also been reported with correlation to
choroidal ischemia and CNV.6 Hepatitis-C itself is
believed to cause an increase in photocoagulated
phospholipids resulting in hypercoagulable state,
especially when combined with IFN-alpha treatment
with production of thrombogenic auto-antibodies.7
Interestingly as IFN has angiostatic property and inhibits
the proliferation and migration of vascular endothelial
cells, it has also been used to treat CNV in age-related
macular degeneration. However, results of these studies
are inconclusive with a need for further randomized
trials.8
Ocular ischemic changes are more reported in patients
with history of DM, HTN and with increased lipids and it
is also believed that these changes settle down with
termination of IFN-alpha therapy.9 Choroidal neovas-
cularization in one eye after IFN-alpha therapy has
already  been reported.10 Other rare findings related to
IFN-alpha therapy include anterior ischemic optic
neuropathy, papilloedema, retinal artery occlusion,
central retinal vein occlusion and pan-uveitis.4 This
patient last used IFN-alpha 6 months ago and did not
have any other associated risk factors, such as DM,
HTN or raised lipids.
REFERENCES
1. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta
SK, et al. Pegylated interferon alfa-2b, pharmacokinetics,
pharmacodynamics, safety and preliminary efficacy data:
hepatitis-C intervention therapy group. Clin Pharmacol Ther
2000; 68:556-67.
2. Adams S, Ostermeier M. Retinopathy associated with
pegylated interferon and ribavirin treatment for chronic
hepatitis-C. Optometry 2010; 81:580-6.
3. Panetta JD, Gilani H. Interferon-induced retinopathy and its
risk in patients with diabetes and hypertension undergoing
treatment for chronic hepatitis-C virus infection. Aliment
Pharmacol Ther 2009; 30:597-602.
4. Kadayifcilar S, Boyacioglu S, Kart H, Gursoy M, Aydin P.
Ocular complications with high-dose interferon alpha in chronic
acute hepatitis. Eye 1999; 13:241-6.
5. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishi K, Okijima T.
Retinal complications and plasma C 5a levels during interferon
alpha therapy for chronic hepatitis. Am J Gastroentrol 1998;
93: 2441-4.
6. Andrade R, Gonzales J, Vazquez L. Vascular ophthalmological
side effects associated with antiviral therapy for chronic
hepatitis-C are related to vascular endothelial growth factor
levels. Antivir Ther 2006; 11:491-8.
7. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy
in chronic hepatitis-C patient during interferon treatment with
ribavirin. Br J Ophthalmol 2001; 85:1171-3.
8. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of
choroidal neovascularization by alpha interferon. An efficacy
and toxicity study. Ophthalmology 1994; 101:289-300.
9. Okuse C, Yotsoyanagi H, Nagase Y. Risk factors for
retinopathy associated with interferon alpha-2b and ribavirin
combination therapy in patients with chronic hepatitis. World J
Gastroenterol 2006; 12:2756-9.
10. Bazarah SM, Ritenour R, Patel ST, Hirsch G, Peltekian KM,
Cruess AF. Choroidal neovascularization with interferon
associated retinopathy: case report and review of literature.
Ann Hepatol 2006; 5:172-6.
Pir Salim Mahar and Abdul Sami Memon
S46 Journal of the College of Physicians and Surgeons Pakistan 2015, Vol. 25 (Special Supplement 1): S45-S46
Figure 4: OCT showing macular thickness map.
